BioNTech (NASDAQ:BNTX) Sees Unusually-High Trading Volume

BioNTech SE (NASDAQ:BNTX) saw strong trading volume on Thursday . 469,548 shares traded hands during mid-day trading, a decline of 29% from the previous session’s volume of 660,687 shares.The stock last traded at $98.58 and had previously closed at $102.30.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of research analyst reports. UBS Group lowered their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. The Goldman Sachs Group lowered their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. TD Cowen increased their target price on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. BMO Capital Markets decreased their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 7th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, BioNTech currently has a consensus rating of “Hold” and a consensus target price of $111.70.

BioNTech Stock Down 2.1 %

The stock has a market cap of $23.81 billion, a PE ratio of 199.60 and a beta of 0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The business has a fifty day moving average of $90.71 and a 200-day moving average of $95.89.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Equities research analysts anticipate that BioNTech SE will post -1.99 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its position in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the period. CWM LLC raised its stake in BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the last quarter. Frazier Financial Advisors LLC purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $30,000. Covestor Ltd acquired a new position in BioNTech during the third quarter worth $32,000. Finally, First Horizon Advisors Inc. purchased a new stake in shares of BioNTech in the fourth quarter valued at about $38,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.